Dry powder formulation of plasmid DNA and siRNA for inhalation

Current Pharmaceutical Design

Volumn 21, Issue 27, 2015, Pages 3854-3866

  Chow, Michael Y T ^a   Lam, Jenny K W ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

DNA; Dry powder; Pulmonary delivery; SiRNA; Spray drying; Spray freeze drying; Supercritical fluid

Indexed keywords

NUCLEIC ACID; PLASMID DNA; SMALL INTERFERING RNA; DNA; POWDER;

ANTIVIRAL ACTIVITY; AQUEOUS SOLUTION; ARTICLE; BIOLOGICAL ACTIVITY; COMPARATIVE STUDY; DRUG FORMULATION; DRY POWDER; DRY POWDER INHALER; FREEZE DRYING; GENE EXPRESSION; HUMAN; IN VITRO GENE TRANSFER; IN VITRO STUDY; MECHANICAL STRESS; METERED DOSE INHALER; NEBULIZER; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SPRAY DRYING; SUPERCRITICAL FLUID; TEMPERATURE STRESS; ADMINISTRATION AND DOSAGE; CHEMISTRY; GENETICS; INHALATIONAL DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; PLASMID; POWDER;

ADMINISTRATION, INHALATION; CHEMISTRY, PHARMACEUTICAL; DNA; FREEZE DRYING; HUMANS; PLASMIDS; POWDERS; RNA, SMALL INTERFERING;

EID: 84947747408     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666150820105916     Document Type: Article

References (138)

1. Friedmann T. Progress toward human gene therapy. Science 1989; 244: 1275-81.
2. Miller AD. Human gene therapy comes of age. Nature 1992; 357: 455-60.
3. Verma IM, Weitzman MD. Gene therapy: twenty-first century medicine. Annu Rev Biochem 2005; 74: 711-38.
4. Burnett JC, Rossi JJ, Tiemann K. Current progress of siRNA/ shRNA therapeutics in clinical trials. Biotechnol J 2011; 6: 1130- 46.
5. Ni X, Castanares M, Mukherjee A, Lupold SE. Nucleic acid aptamers: clinical applications and promising new horizons. Curr Med Chem 2011; 18: 4206-14.
6. Pereira DM, Rodrigues PM, Borralho PM, Rodrigues CM. Delivering the promise of miRNA cancer therapeutics. Drug Discov Today 2013; 18: 282-9.
7. Que-Gewirth NS, Sullenger BA. Gene therapy progress and prospects: RNA aptamers. Gene Ther 2007; 14: 283-91.
8. Uhlmann E, Peyman A. Antisense oligonucleotides: a new therapeutic principle. Chem Rev 1990; 90: 543-84.
9. Xia H, Mao Q, Paulson HL, Davidson BL. siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 2002; 20: 1006-10.
10. Barik S, Bitko V. Prospects of RNA interference therapy in respiratory viral diseases: update 2006. Expert Opin Biol Ther 2006; 6: 1151-60.
11. DeVincenzo JP. The promise, pitfalls and progress of RNAinterference- based antiviral therapy for respiratory viruses. Antivir Ther 2012; 17: 213-25.
12. Ferrari S, Geddes DM, Alton EW. Barriers to and new approaches for gene therapy and gene delivery in cystic fibrosis. Adv Drug Deliv Rev 2002; 54: 1373-93.
13. Ge Q, Filip L, Bai A, Nguyen T, Eisen HN, Chen J. Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci USA 2004; 101: 8676-81.
14. Ge Q, McManus MT, Nguyen T, et al. RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription. Proc Natl Acad Sci USA 2003; 100: 2718-23.
15. Griesenbach U, Geddes DM, Alton EW. Gene therapy progress and prospects: cystic fibrosis. Gene Ther 2006; 13: 1061-7.
16. Moon C, Oh Y, Roth JA. Current status of gene therapy for lung cancer and head and neck cancer. Clin Cancer Res 2003; 9: 5055- 67.
17. Rosas-Taraco AG, Higgins DM, Sanchez-Campillo J, Lee EJ, Orme IM, Gonzalez-Juarrero M. Intrapulmonary delivery of XCL1-targeting small interfering RNA in mice chronically infected with Mycobacterium tuberculosis. Am J Respir Cell Mol Biol 2009; 41: 136-45.
18. Seguin RM, Ferrari N. Emerging oligonucleotide therapies for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2009; 18: 1505-17.
19. Zarogouldis P, Karamanos NK, Porpodis K, et al. Vectors for inhaled gene therapy in lung cancer. Application for nano oncology and safety of bio nanotechnology. Int J Mol Sci 2012; 13: 10828- 62.
20. Senoo T, Hattori N, Tanimoto T, et al. Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis. Thorax 2010; 65: 334-40.
21. Goh FY, Cook KL, Upton N, et al. Receptor-interacting protein 2 gene silencing attenuates allergic airway inflammation. J Immunol 2013; 191: 2691-9.
22. Perl M, Chung CS, Lomas-Neira J, et al. Silencing of Fas, but not caspase-8, in lung epithelial cells ameliorates pulmonary apoptosis, inflammation, and neutrophil influx after hemorrhagic shock and sepsis. Am J Pathol 2005; 167: 1545-59.
23. Moschos SA, Frick M, Taylor B, et al. Uptake, efficacy, and systemic distribution of naked, inhaled short interfering RNA (siRNA) and locked nucleic acid (LNA) antisense. Mol Ther 2011; 19: 2163-8.
24. Moschos SA, Spinks K, Williams AE, Lindsay MA. Targeting the lung using siRNA and antisense based oligonucleotides. Curr Pharm Des 2008; 14: 3620-7.
25. Robbins M, Judge A, Ambegia E, et al. Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Hum Gene Ther 2008; 19: 991-9.
26. DeVincenzo J, Lambkin-Williams R, Wilkinson T, et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci USA 2010; 107: 8800-5.
27. DeVincenzo JP, Wilkinson T, Vaishnaw A, et al. Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am J Respir Crit Care Med 2010; 182: 1305-14.
28. Mizuno T, Mohri K, Nasu S, Danjo K, Okamoto H. Dual imaging of pulmonary delivery and gene expression of dry powder inhalant by fluorescence and bioluminescence. J Control Release 2009; 134: 149-54.
29. Okamoto H, Nishida S, Todo H, Sakakura Y, Iida K, Danjo K. Pulmonary gene delivery by chitosan-pDNA complex powder prepared by a supercritical carbon dioxide process. J Pharm Sci 2003; 92: 371-80.
30. Beck-Broichsitter M, Merkel OM, Kissel T. Controlled pulmonary drug and gene delivery using polymeric nano-carriers. J Control Release 2012; 161: 214-24.
31. Lam JK, Liang W, Chan HK. Pulmonary delivery of therapeutic siRNA. Adv Drug Deliv Rev 2012; 64: 1-15.
32. Merkel OM, Rubinstein I, Kissel T. siRNA delivery to the lung: what's new? Adv Drug Deliv Rev 2014; 75: 112-28.
33. Merkel OM, Zheng M, Debus H, Kissel T. Pulmonary gene delivery using polymeric nonviral vectors. Bioconjug Chem 2012; 23: 3- 20.
34. Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG. Non-viral vectors for gene-based therapy. Nat Rev Genet 2014; 15: 541-55.
35. Stein SW, Sheth P, Hodson PD, Myrdal PB. Advances in metered dose inhaler technology: hardware development. AAPS Pharm- SciTech 2014; 15: 326-38.
36. Kim K-H, Shon Z-H, Nguyen HT, Jeon EC. A review of major chlorofluorocarbons and their halocarbon alternatives in the air. Atmos Environ 2011; 45: 1369-82.
37. Tsai WT. An overview of environmental hazards and exposure risk of hydrofluorocarbons (HFCs). Chemosphere 2005; 61: 1539-47.
38. Vervaet C, Byron PR. Drug-surfactant-propellant interactions in HFA-formulations. Int J Pharm 1999; 186: 13-30.
39. Myrdal PB, Sheth P, Stein SW. Advances in metered dose inhaler technology: formulation development. AAPS PharmSciTech 2014; 15: 434-55.
40. Sanchis J, Corrigan C, Levy ML, Viejo JL, Group A. Inhaler devices - from theory to practice. Respir Med 2013; 107: 495-502.
41. Agu RU, Ugwoke MI, Armand M, Kinget R, Verbeke N. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir Res 2001; 2: 198-209.
42. Chew NY, Chan HK. The role of particle properties in pharmaceutical powder inhalation formulations. J Aerosol Med 2002; 15: 325- 30.
43. Hertel S, Pohl T, Friess W, Winter G. That's cool!--Nebulization of thermolabile proteins with a cooled vibrating mesh nebulizer. Eur J Pharm Biopharm 2014; 87: 357-65.
44. Walther W, Stein U, Voss C, Schmidt T, Schleef M, Schlag PM. Stability analysis for long-term storage of naked DNA: impact on nonviral in vivo gene transfer. Anal Biochem 2003; 318: 230-5.
45. Newhouse MT, Hirst PH, Duddu SP, et al. Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. Chest 2003; 124: 360-6.
46. Traini D, Young PM. Delivery of antibiotics to the respiratory tract: an update. Expert Opin Drug Deliv 2009; 6: 897-905.
47. Grasmeijer F, Hagedoorn P, Frijlink HW, de Boer AH. Characterisation of high dose aerosols from dry powder inhalers. Int J Pharm 2012; 437: 242-9.
48. Zhou QT, Tang P, Leung SS, Chan JG, Chan HK. Emerging inhalation aerosol devices and strategies: where are we headed? Adv Drug Deliv Rev 2014; 75: 3-17.
49. Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm 2010; 392: 1-19.
50. Snipes MB, Clem MF. Retention of microspheres in the rat lung after intratracheal instillation. Environ Res 1981; 24: 33-41.
51. Okuda T, Kito D, Oiwa A, Fukushima M, Hira D, Okamoto H. Gene silencing in a mouse lung metastasis model by an inhalable dry small interfering RNA powder prepared using the supercritical carbon dioxide technique. Biol Pharm Bull 2013; 36: 1183-91.
52. Maa YF, Nguyen PA, Sweeney T, Shire SJ, Hsu CC. Protein inhalation powders: spray drying vs spray freeze drying. Pharm Res 1999; 16: 249-54.
53. Adi H, Traini D, Chan HK, Young PM. The influence of drug morphology on aerosolisation efficiency of dry powder inhaler formulations. J Pharm Sci 2008; 97: 2780-8.
54. Chew NY, Chan HK. Use of solid corrugated particles to enhance powder aerosol performance. Pharm Res 2001; 18: 1570-7.
55. Kwok PC, Tunsirikongkon A, Glover W, Chan HK. Formation of protein nano-matrix particles with controlled surface architecture for respiratory drug delivery. Pharm Res 2011; 28: 788-96.
56. Vehring R. Pharmaceutical particle engineering via spray drying. Pharm Res 2008; 25: 999-1022.
57. Chawla A, Taylor KMG, Newton JM, Johnson MCR. Production of spray dried salbutamol sulphate for use in dry powder aerosol formulation. Int J Pharm 1994; 108: 233-40.
58. Prinn KB, Costantino HR, Tracy M. Statistical modeling of protein spray drying at the lab scale. AAPS PharmSciTech 2002; 3: E4.
59. Mohajel N, Najafabadi AR, Azadmanesh K, et al. Optimization of a spray drying process to prepare dry powder microparticles containing plasmid nanocomplex. Int J Pharm 2012; 423: 577-85.
60. Reese HR, Zimm BH. Fracture of polymer chains in extensional flow: Experiments with DNA, and a molecular-dynamics simulation. J Chem Phys 1990; 92: 2650-62.
61. Kuo JH. The effect of protective agents on the stability of plasmid DNA by the process of spray-drying. J Pharm Pharmacol 2003; 55: 301-6.
62. Kuo JH, Lo YL, Shau MD, Cherng JY. A thermodynamic study of cationic polymer-plasmid DNA complexes by highly-sensitive differential scanning calorimetry. J Control Release 2002; 81: 321-5.
63. Aghbashlo M, Mobli H, Rafiee S, Madadlou A. The use of artificial neural network to predict exergetic performance of spray drying process: A preliminary study. Comput Electron Agr 2012; 88: 32-43.
64. Li HY, Neill H, Innocent R, Seville P, Williamson I, Birchall JC. Enhanced dispersibility and deposition of spray-dried powders for pulmonary gene therapy. J Drug Target 2003; 11: 425-32.
65. Li HY, Seville PC, Williamson IJ, Birchall JC. The use of amino acids to enhance the aerosolisation of spray-dried powders for pulmonary gene therapy. J Gene Med 2005; 7: 343-53.
66. Mohajel N, Najafabadi AR, Azadmanesh K, et al. Drying of a plasmid containing formulation: chitosan as a protecting agent. Daru 2012; 20: 22.
67. Li HY, Seville PC, Williamson IJ, Birchall JC. The use of absorption enhancers to enhance the dispersibility of spray-dried powders for pulmonary gene therapy. J Gene Med 2005; 7: 1035-43.
68. Li HY, Birchall J. Chitosan-modified dry powder formulations for pulmonary gene delivery. Pharm Res 2006; 23: 941-50.
69. Liang W, Kwok PC, Chow MY, et al. Formulation of pH responsive peptides as inhalable dry powders for pulmonary delivery of nucleic acids. Eur J Pharm Biopharm 2014; 86: 64-73.
70. Liang W, Chow MY, Lau PN, et al. Inhalable dry powder formulations of siRNA and pH responsive peptides with antiviral activity against H1N1 influenza virus. Mol Pharm 2015; 12(3): 910-21.
71. Jensen DM, Cun D, Maltesen MJ, Frokjaer S, Nielsen HM, Foged C. Spray drying of siRNA-containing PLGA nanoparticles intended for inhalation. J Control Release 2010; 142: 138-45.
72. Jensen DK, Jensen LB, Koocheki S, et al. Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA. J Control Release 2012; 157: 141-8.
73. D'Addio SM, Chan JG, Kwok PC, Prud'homme RK, Chan HK. Constant size, variable density aerosol particles by ultrasonic spray freeze drying. Int J Pharm 2012; 427: 185-91.
74. Kuo JH, Hwang R. Preparation of DNA dry powder for non-viral gene delivery by spray-freeze drying: effect of protective agents (polyethyleneimine and sugars) on the stability of DNA. J Pharm Pharmacol 2004; 56: 27-33.
75. Costantino HR, Firouzabadian L, Hogeland K, et al. Protein sprayfreeze drying. Effect of atomization conditions on particle size and stability. Pharm Res 2000; 17: 1374-83.
76. Webb SD, Golledge SL, Cleland JL, Carpenter JF, Randolph TW. Surface adsorption of recombinant human interferon-gamma in lyophilized and spray-lyophilized formulations. J Pharm Sci 2002; 91: 1474-87.
77. Yu Z, Johnston KP, Williams RO, 3rd. Spray freezing into liquid versus spray-freeze drying: influence of atomization on protein aggregation and biological activity. Eur J Pharm Sci 2006; 27: 9-18.
78. Chang LL, Pikal MJ. Mechanisms of protein stabilization in the solid state. J Pharm Sci 2009; 98: 2886-908.
79. Allison SD, Molina MC, Anchordoquy TJ. Stabilization of lipid/DNA complexes during the freezing step of the lyophilization process: the particle isolation hypothesis. Biochim Biophys Acta 2000; 1468: 127-38.
80. Chang L, Shepherd D, Sun J, et al. Mechanism of protein stabilization by sugars during freeze-drying and storage: native structure preservation, specific interaction, and/or immobilization in a glassy matrix? J Pharm Sci 2005; 94: 1427-44.
81. Adami RC, Collard WT, Gupta SA, Kwok KY, Bonadio J, Rice KG. Stability of peptide-condensed plasmid DNA formulations. J Pharm Sci 1998; 87: 678-83.
82. Mohri K, Okuda T, Mori A, Danjo K, Okamoto H. Optimized pulmonary gene transfection in mice by spray-freeze dried powder inhalation. J Control Release 2010; 144: 221-6.
83. Tsukamoto M, Okuda T, Okamoto H, et al. Bovine serum albumin as a lyoprotectant for preparation of DNA dry powder formulations using the spray-freeze drying method. Biol Pharm Bull 2012; 35: 1178-81.
84. Jovanovic N, Bouchard A, Hofland GW, Witkamp GJ, Crommelin DJ, Jiskoot W. Stabilization of proteins in dry powder formulations using supercritical fluid technology. Pharm Res 2004; 21: 1955-69.
85. Shoyele SA, Cawthorne S. Particle engineering techniques for inhaled biopharmaceuticals. Adv Drug Deliv Rev 2006; 58: 1009- 29.
86. Cape SP, Villa JA, Huang ET, Yang TH, Carpenter JF, Sievers RE. Preparation of active proteins, vaccines and pharmaceuticals as fine powders using supercritical or near-critical fluids. Pharm Res 2008; 25: 1967-90.
87. Jovanovic N, Bouchard A, Sutter M, et al. Stable sugar-based protein formulations by supercritical fluid drying. Int J Pharm 2008; 346: 102-8.
88. Okamoto H, Danjo K. Application of supercritical fluid to preparation of powders of high-molecular weight drugs for inhalation. Adv Drug Deliv Rev 2008; 60: 433-46.
89. Türk M. Formation of small organic particles by RESS: experimental and theoretical investigations. J Supercrit Fluids 1999; 15: 79- 89.
90. Huang Z, Sun G-B, Chiew YC, Kawi S. Formation of ultrafine aspirin particles through rapid expansion of supercritical solutions (RESS). Powder Technol 2005; 160: 127-34.
91. Kayrak D, Akman U, Hortaçsu Ö. Micronization of Ibuprofen by RESS. J Supercrit Fluids 2003; 26: 17-31.
92. Yasuji T, Takeuchi H, Kawashima Y. Particle design of poorly water-soluble drug substances using supercritical fluid technologies. Adv Drug Deliv Rev 2008; 60: 388-98.
93. Okamoto H, Sakakura Y, Shiraki K, et al. Stability of chitosanpDNA complex powder prepared by supercritical carbon dioxide process. Int J Pharm 2005; 290: 73-81.
94. Okamoto H, Shiraki K, Yasuda R, Danjo K, Watanabe Y. Chitosan- interferon-beta gene complex powder for inhalation treatment of lung metastasis in mice. J Control Release 2011; 150: 187-95.
95. Bouchard A, Jovanović N, Jiskoot W, et al. Lysozyme particle formation during supercritical fluid drying: Particle morphology and molecular integrity. J Supercrit Fluids 2007; 40: 293-307.
96. Rehman M, Shekunov BY, York P, et al. Optimisation of powders for pulmonary delivery using supercritical fluid technology. Eur J Pharm Sci 2004; 22: 1-17.
97. Thiering R, Dehghani F, Foster NR. Current issues relating to antisolvent micronisation techniques and their extension to industrial scales. J Supercrit Fluids 2001; 21: 159-77.
98. Colonna C, Conti B, Genta I, Alpar OH. Non-viral dried powders for respiratory gene delivery prepared by cationic and chitosan loaded liposomes. Int J Pharm 2008; 364: 108-18.
99. Nguyen XC, Herberger JD, Burke PA. Protein powders for encapsulation: a comparison of spray-freeze drying and spray drying of darbepoetin alfa. Pharm Res 2004; 21: 507-14.
100. Dontireddy R, Crean AM. A comparative study of spray-dried and freeze-dried hydrocortisone/polyvinyl pyrrolidone solid dispersions. Drug Dev Ind Pharm 2011; 37: 1141-9.
101. Kondo M, Niwa T, Okamoto H, Danjo K. Particle characterization of poorly water-soluble drugs using a spray freeze drying technique. Chem Pharm Bull (Tokyo) 2009; 57: 657-62.
102. Hagerman PJ. Flexibility of RNA. Annu Rev Biophys Biomol Struct 1997; 26: 139-56.
103. Kebbekus P, Draper DE, Hagerman P. Persistence length of RNA. Biochemistry 1995; 34: 4354-7.
104. Newman SP, Wilding IR, Hirst PH. Human lung deposition data: the bridge between in vitro and clinical evaluations for inhaled drug products? Int J Pharm 2000; 208: 49-60.
105. Yang MY, Chan JG, Chan HK. Pulmonary drug delivery by powder aerosols. J Control Release 2014; 193C: 228-40.
106. Agu RU, Ugwoke MI. In vitro and in vivo testing methods for respiratory drug delivery. Expert Opin Drug Deliv 2011; 8: 57-69.
107. Mitchell JP, Nagel MW. Cascade impactors for the size characterization of aerosols from medical inhalers: their uses and limitations. J Aerosol Med 2003; 16: 341-77.
108. Mitchell J, Newman S, Chan HK. In vitro and in vivo aspects of cascade impactor tests and inhaler performance: a review. AAPS PharmSciTech 2007; 8: E110.
109. Zhang J, Wu L, Chan HK, Watanabe W. Formation, characterization, and fate of inhaled drug nanoparticles. Adv Drug Deliv Rev 2011; 63: 441-55.
110. Hickey AJ, Mansour HM, Telko MJ, et al. Physical characterization of component particles included in dry powder inhalers. I. Strategy review and static characteristics. J Pharm Sci 2007; 96: 1282-301.
111. Kaialy W, Nokhodchi A. Treating mannitol in a saturated solution of mannitol: a novel approach to modify mannitol crystals for improved drug delivery to the lungs. Int J Pharm 2013; 448: 58-70.
112. Begat P, Morton DA, Staniforth JN, Price R. The cohesiveadhesive balances in dry powder inhaler formulations I: Direct quantification by atomic force microscopy. Pharm Res 2004; 21: 1591-7.
113. Shah B, Kakumanu VK, Bansal AK. Analytical techniques for quantification of amorphous/crystalline phases in pharmaceutical solids. J Pharm Sci 2006; 95: 1641-65.
114. Larhrib H, Martin GP, Prime D, Marriott C. Characterisation and deposition studies of engineered lactose crystals with potential for use as a carrier for aerosolised salbutamol sulfate from dry powder inhalers. Eur J Pharm Sci 2003; 19: 211-21.
115. Yang XB, Wang XB, Pan WS, et al. Optimization and characterization of dry powder of fanhuncaoin for inhalation based on selection of excipients. Chem Pharm Bull (Tokyo) 2011; 59: 929-37.
116. Hulse WL, Forbes RT, Bonner MC, Getrost M. The characterization and comparison of spray-dried mannitol samples. Drug Dev Ind Pharm 2009; 35: 712-8.
117. Pfeifer C, Hasenpusch G, Uezguen S, et al. Dry powder aerosols of polyethylenimine (PEI)-based gene vectors mediate efficient gene delivery to the lung. J Control Release 2011; 154: 69-76.
118. Lane ME, Brennan FS, Corrigan OI. Comparison of postemulsification freeze drying or spray drying processes for the microencapsulation of plasmid DNA. J Pharm Pharmacol 2005; 57: 831-8.
119. Forbes II. Human airway epithelial cell lines for in vitro drug transport and metabolism studies. Pharm Sci Technolo Today 2000; 3: 18-27.
120. de Souza Carvalho C, Daum N, Lehr CM. Carrier interactions with the biological barriers of the lung: advanced in vitro models and challenges for pulmonary drug delivery. Adv Drug Deliv Rev 2014; 75: 129-40.
121. Seville PC, Kellaway IW, Birchall JC. Preparation of dry powder dispersions for non-viral gene delivery by freeze-drying and spraydrying. J Gene Med 2002; 4: 428-37.
122. Pezzulo AA, Starner TD, Scheetz TE, et al. The air-liquid interface and use of primary cell cultures are important to recapitulate the transcriptional profile of in vivo airway epithelia. Am J Physiol Lung Cell Mol Physiol 2011; 300: L25-31.
123. Stewart CE, Torr EE, Mohd Jamili NH, Bosquillon C, Sayers I. Evaluation of differentiated human bronchial epithelial cell culture systems for asthma research. J Allergy (Cairo) 2012; 2012: 943982.
124. Hutter V, Hilgendorf C, Cooper A, Zann V, Pritchard DI, Bosquillon C. Evaluation of layers of the rat airway epithelial cell line RL- 65 for permeability screening of inhaled drug candidates. Eur J Pharm Sci 2012; 47: 481-9.
125. Grainger CI, Greenwell LL, Martin GP, Forbes B. The permeability of large molecular weight solutes following particle delivery to air-interfaced cells that model the respiratory mucosa. Eur J Pharm Biopharm 2009; 71: 318-24.
126. Taube C, Dakhama A, Gelfand EW. Insights into the pathogenesis of asthma utilizing murine models. Int Arch Allergy Immunol 2004; 135: 173-86.
127. Gelfand EW. Pro: mice are a good model of human airway disease. Am J Respir Crit Care Med 2002; 166: 5-6.
128. Raeburn D, Underwood SL, Villamil ME. Techniques for drug delivery to the airways, and the assessment of lung function in animal models. J Pharmacol Toxicol Methods 1992; 27: 143-59.
129. Nadithe V, Rahamatalla M, Finlay WH, Mercer JR, Samuel J. Evaluation of nose-only aerosol inhalation chamber and comparison of experimental results with mathematical simulation of aerosol deposition in mouse lungs. J Pharm Sci 2003; 92: 1066-76.
130. McConville JT, Williams RO 3rd, Carvalho TC, et al. Design and evaluation of a restraint-free small animal inhalation dosing chamber. Drug Dev Ind Pharm 2005; 31: 35-42.
131. Sinha B, Mukherjee B. Development of an inhalation chamber and a dry powder inhaler device for administration of pulmonary medication in animal model. Drug Dev Ind Pharm 2012; 38: 171-9.
132. Hoppentocht M, Hoste C, Hagedoorn P, Frijlink HW, de Boer AH. In vitro evaluation of the DP-4M PennCentury insufflator. Eur J Pharm Biopharm 2014; 88: 153-9.
133. Brown RH, Walters DM, Greenberg RS, Mitzner W. A method of endotracheal intubation and pulmonary functional assessment for repeated studies in mice. J Appl Physiol (1985) 1999; 87: 2362-5.
134. Lizio R, Westhof A, Lehr CM, Klenner T. Oral endotracheal intubation of rats for intratracheal instillation and aerosol drug delivery. Lab Anim 2001; 35: 257-60.
135. Hamacher J, Arras M, Bootz F, Weiss M, Schramm R, Moehrlen U. Microscopic wire guide-based orotracheal mouse intubation: description, evaluation and comparison with transillumination. Lab Anim 2008; 42: 222-30.
136. Spoelstra EN, Ince C, Koeman A, et al. A novel and simple method for endotracheal intubation of mice. Lab Anim 2007; 41: 128-35.
137. Duret C, Wauthoz N, Merlos R, et al. In vitro and in vivo evaluation of a dry powder endotracheal insufflator device for use in dose-dependent preclinical studies in mice. Eur J Pharm Biopharm 2012; 81: 627-34.
138. Morello M, Krone CL, Dickerson S, et al. Dry-powder pulmonary insufflation in the mouse for application to vaccine or drug studies. Tuberculosis (Edinb) 2009; 89: 371-7.